Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating DNA, Circulating RNA, Circulating Tumor Cells

Brian Dougherty's Biography

Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D

Brian is the Executive Director of Translational Genomics Oncology at AstraZeneca Pharmaceuticals in Boston, MA leading AstraZeneca’s cancer genomics efforts. He oversees a team of lab scientists and computational biologists applying leading-edge genomic and advanced algorithmic technologies to deliver on Precision Medicine - matching the right patient with the right drug. This includes biomarker development, patient selection and monitoring strategies, identifying new tumor drug resistance mechanisms, researching genetics-based translational hypotheses, and delivering novel cancer targets. When he was previously at Bristol-Myers Squibb, Pfizer, TIGR and Amgen, Brian led sequencing, genotyping, gene expression, high-content imaging, and functional genomics lab efforts, applying technologies to enable the discovery and development of medicines for diseases such as cancer, infectious diseases, chronic pain, and Alzheimer’s Disease.

Brian holds a B.A. from the University of Delaware, a Ph.D. from Wake Forest University Medical Center, an M.B.A from the University of New Haven, and completed a postdoctoral research fellowship in the laboratory of Nobel laureate Hamilton O. Smith at The Johns Hopkins University School of Medicine.

Brian Dougherty Image

Development of Circulating Tumor DNA Biomarkers using Next Generation Sequencing

Monday, 23 March 2015 at 16:00

Add to Calendar ▼2015-03-23 16:00:002015-03-23 17:00:00Europe/LondonDevelopment of Circulating Tumor DNA Biomarkers using Next Generation

Detection of mutations from plasma-derived circulating tumor DNA presents a number of technical challenges. In-house Next Gen Sequencing is being developed with the goal of inexpensive, accurate, high-sensitivity mutation detection, and a number of external collaborations and fee-for-service agreements have been established to further refine this technology.

Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating DNA, Circulating RNA, Circulating Tumor